Serum Galectin-3: diagnostic value for papillary thyroid carcinoma

Area of Science:

• Endocrinology
• Oncology
• Biochemistry

Background:

• Thyroid cancer is a significant endocrine malignancy, necessitating improved diagnostic markers.
• Accurate pre-operative differentiation between benign and malignant thyroid nodules remains a clinical challenge.
• Current diagnostic methods may lead to unnecessary aggressive interventions for benign nodules.

Purpose of the Study:

• To evaluate the diagnostic utility of preoperative serum Galectin-3 levels in thyroid cancer.
• To assess Galectin-3 as a marker for distinguishing malignant from benign thyroid nodules.
• To reduce unnecessary aggressive treatments for thyroid nodules.

Main Methods:

• Prospective study of 64 patients operated between May 2009 and April 2011.
• Exclusion of patients with toxic nodules or pre-existing malignancy diagnosis via fine needle aspiration biopsy (FNAB).
• Inclusion of patients with thyroid nodules >3 cm or suspicious FNAB findings; groups defined by postoperative pathology.

Main Results:

• The study included 50 patients in the control group and 14 in the cancer group.
• No statistically significant difference in mean age between the control and cancer groups.
• A statistically significant difference in serum Galectin-3 levels was observed between the cancer and control groups (p<0.001).

Conclusions:

• Serum Galectin-3 levels are significantly elevated in patients with malignant thyroid nodules.
• Preoperative serum Galectin-3 shows diagnostic value in differentiating thyroid malignancies.
• This marker may assist in clinical decision-making for thyroid nodule management.